{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-283537","form_type":"8-K","ticker":"RCEL","cik":"0001762303","company_name":"AVITA Medical, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.027348+00:00","generated_at":"2026-06-21T20:48:22.888133+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AVITA Medical Q3 commercial rev $9.0M, up 30%; raises FY guidance; pivotal trial endpoints met","bullets":["Commercial revenue (ex-BARDA) $9.0M, +30% YoY; total revenue $9.1M.","Net loss $5.6M ($0.22/sh); cash $88.2M, no debt.","Soft-tissue repair trial met co-primary endpoints; vitiligo trial achieved super-superiority.","FY 2022 commercial revenue guidance raised to $33-34M from $30M.","Japan MHLW grants RECELL approval; partner COSMOTEC launching in Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-283537","json":"https://secwatch.observer/filing/0001193125-22-283537.json","markdown":"https://secwatch.observer/filing/0001193125-22-283537.md","text":"https://secwatch.observer/filing/0001193125-22-283537.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1762303/000119312522283537/0001193125-22-283537-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1762303/000119312522283537/d384818d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:48:22.888133+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"35d10d6a33bc054caf93c246b41f8f3cc2d12e48","claim":"AVITA Medical, Inc. reported full year 2022 results: revenue $33.0-34.0 million. Guidance raised.","evidence_excerpt":"full year 2022 commercial revenue (excluding BARDA revenues) is expected to be $33.0-34.0 million, an increase from our prior guidance of $30 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1762303/000119312522283537/0001193125-22-283537-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2022"},{"label":"Revenue","value":"$33.0-34.0 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"c1f5f1f11216a91b4271b255956ab34d9e975b70","claim":"AVITA Medical, Inc. reported third quarter ended September 30, 2022 results: revenue $9.0 million, net income $5.6 million, EPS $0.22 per share.","evidence_excerpt":"Reported commercial revenue, which excludes BARDA revenue, of $9.0 million, a 30% increase compared to $6.9 million in the corresponding period in the prior year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1762303/000119312522283537/0001193125-22-283537-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$9.0 million"},{"label":"Net income","value":"$5.6 million"},{"label":"EPS","value":"$0.22 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}